JNJ-1661010 is a selective inhibitor of the Nav1.8 voltage-gated sodium channel, primarily researched for its potential therapeutic applications in treating neuropathic and chronic pain. It works by blocking sodium influx in peripheral sensory neurons, thereby modulating pain signaling without significantly affecting central nervous system functions. This compound is being investigated in preclinical and clinical studies to assess its efficacy, safety profile, and optimal dosing for pain management, particularly in conditions where standard analgesics are inadequate. It is not currently indicated for neurological disorders like Parkinson's, anxiety, or depression.